Back to MORGAN STANLEY MORGAN STANLEY

SCNISCNI
Showing 8 of 9 quarters

Position history for MORGAN STANLEYMORGAN STANLEY's holdings in BIONDVAX PHARMACEUTICALS LTD

Yes. Morgan Stanley holds 58 shares of SCNI (Biondvax Pharmaceuticals), worth $15, as of its Q2 2026 13F filing. The share count is unchanged from Q1 2026. Morgan Stanley has held SCNI in every 13F on record since Q2 2024, 9 quarterly filings.

Current Value

$15

Current Shares

58

Total Value Change

-$865

Total Shares Change

-197

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Unchanged
58
0.0%
$150.0%$0.25
0
2026-Q1
Unchanged
58
0.0%
$330.0%$0.80
0
2025-Q4
Decreased
58
-76.3%
$410.0%$0.72
0
2025-Q3
Decreased
245
-3.9%
$3100.0%$1.20
0
2025-Q2
Unchanged
255
0.0%
$5810.0%$2.28
0
2025-Q1
Unchanged
255
0.0%
$6870.0%$2.80
0
2024-Q4
Unchanged
255
0.0%
$8530.0%$33.45
0
2024-Q3
Unchanged
255
0.0%
$8800.0%$34.50
0

Other major holders of SCNI: UBS Group AG, CITADEL ADVISORS LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used